JW

John Wilson

AFT Pharmaceuticals Limited | Non-Executive Director
Mr Wilson was a New Zealand physician and academic. He joined an International pharmaceutical company, Boehringer Ingelheim, working in their US subsidiary, becoming their Head of Medical Research and Regulatory Affairs, the interface with FDA, playing a role in steering 10 drugs through the FDA to the US and global markets. He moved to Head Office in Germany, being responsible for those same functions for worldwide drug development. He chaired the company's International Medical Committee overseeing the medical aspects of all drugs in development globally, and their Internal Labelling Committee for the drugs on the worldwide market. He was the medical parent of Spiriva, a drug for Chronic Obstructive Pulmonary Disease (COPD), one of the global killers. The drug last year sold $5 billion. He now consults internationally on new drugs in development, and for pharmaceutical companies.

Company and Role

Company
Title
Tenure
Since
AFP
AFT Pharmaceuticals Limited
  • Non-Executive Director
11yrs, 10mthSep 2012

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
AFP
AFT Pharmaceuticals Limited
16/06/17N/A56,689N/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
AFP
AFT Pharmaceuticals Limited
16/06/17
Issued
6,667$2.250$15,000Participation in share purchase plan. Trading in $NZ. As per announcement on 19/06/2017.